Trial Profile
An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Aspirin
- Indications POEMS syndrome
- Focus Therapeutic Use
- 01 Jun 2021 Results evaluating the expression of cereblon, IKZF1, and IKZF3 on gene and protein levels and aimed to correlate the expression of cereblon and its downstream targets in the malignant plasma cells with response to lenalidomide-based treatment in newly diagnosed POEMS syndrome patients and evaluates their association with prognostic parameters published in the Annals of Hematology
- 23 Apr 2017 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology